Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 4
2004 6
2005 3
2006 9
2007 1
2008 4
2009 11
2010 8
2011 8
2012 3
2013 8
2014 13
2015 10
2016 19
2017 12
2018 13
2019 25
2020 29
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

176 results
Results by year
Filters applied: . Clear all
Page 1
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alía EM, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marmé F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P; PAOLA-1 Investigators. Ray-Coquard I, et al. Among authors: pignata s. N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361. N Engl J Med. 2019. PMID: 31851799 Clinical Trial.
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators. Pujade-Lauraine E, et al. Among authors: pignata s. Lancet Oncol. 2017 Sep;18(9):1274-1284. doi: 10.1016/S1470-2045(17)30469-2. Epub 2017 Jul 25. Lancet Oncol. 2017. PMID: 28754483 Clinical Trial.
PARP inhibitors in ovarian cancer.
Franzese E, Centonze S, Diana A, Carlino F, Guerrera LP, Di Napoli M, De Vita F, Pignata S, Ciardiello F, Orditura M. Franzese E, et al. Among authors: pignata s. Cancer Treat Rev. 2019 Feb;73:1-9. doi: 10.1016/j.ctrv.2018.12.002. Epub 2018 Dec 4. Cancer Treat Rev. 2019. PMID: 30543930 Free article. Review.
Treatment of recurrent epithelial ovarian cancer.
Pignata S, Pisano C, Di Napoli M, Cecere SC, Tambaro R, Attademo L. Pignata S, et al. Cancer. 2019 Dec 15;125 Suppl 24:4609-4615. doi: 10.1002/cncr.32500. Cancer. 2019. PMID: 31967680 Free article. Review.
Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications.
Giannone G, Attademo L, Scotto G, Genta S, Ghisoni E, Tuninetti V, Aglietta M, Pignata S, Valabrega G. Giannone G, et al. Among authors: pignata s. Cancers (Basel). 2019 Nov 19;11(11):1820. doi: 10.3390/cancers11111820. Cancers (Basel). 2019. PMID: 31752447 Free PMC article. Review.
State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: When common sense is not enough.
Bersanelli M, Buti S, De Giorgi U, Di Maio M, Giannarelli D, Pignata S, Banna GL. Bersanelli M, et al. Among authors: pignata s. Crit Rev Oncol Hematol. 2019 Jul;139:87-90. doi: 10.1016/j.critrevonc.2019.05.003. Epub 2019 May 8. Crit Rev Oncol Hematol. 2019. PMID: 31112887 Free article. Review.
Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives.
Ventriglia J, Paciolla I, Pisano C, Cecere SC, Di Napoli M, Tambaro R, Califano D, Losito S, Scognamiglio G, Setola SV, Arenare L, Pignata S, Della Pepa C. Ventriglia J, et al. Among authors: pignata s. Cancer Treat Rev. 2017 Sep;59:109-116. doi: 10.1016/j.ctrv.2017.07.008. Epub 2017 Jul 31. Cancer Treat Rev. 2017. PMID: 28800469 Review.
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.
Gori S, Barberis M, Bella MA, Buttitta F, Capoluongo E, Carrera P, Colombo N, Cortesi L, Genuardi M, Gion M, Guarneri V, Incorvaia L, La Verde N, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A; AIOM-SIGU-SIBIOC-SIAPEC-IAP Working Group. Gori S, et al. Among authors: pignata s. Crit Rev Oncol Hematol. 2019 Aug;140:67-72. doi: 10.1016/j.critrevonc.2019.05.012. Epub 2019 May 25. Crit Rev Oncol Hematol. 2019. PMID: 31176273 Free article.
Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives.
Pujade-Lauraine E, Banerjee S, Pignata S. Pujade-Lauraine E, et al. Among authors: pignata s. J Clin Oncol. 2019 Sep 20;37(27):2437-2448. doi: 10.1200/JCO.19.00194. Epub 2019 Aug 12. J Clin Oncol. 2019. PMID: 31403868 Review. No abstract available.
Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.
Cecere SC, Giannone G, Salutari V, Arenare L, Lorusso D, Ronzino G, Lauria R, Cormio G, Carella C, Scollo P, Ghizzoni V, Raspagliesi F, Di Napoli M, Mazzoni E, Marchetti C, Bergamini A, Orditura M, Valabrega G, Scambia G, Maltese G, De Matteis E, Cardalesi C, Loizzi V, Boccia S, Naglieri E, Scandurra G, Pignata S. Cecere SC, et al. Among authors: pignata s. Gynecol Oncol. 2020 Jan;156(1):38-44. doi: 10.1016/j.ygyno.2019.10.023. Epub 2019 Nov 4. Gynecol Oncol. 2020. PMID: 31699415 Free article.
176 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback